Testing Two Treatments Together for Schizophrenia Symptoms
Tests an NMDA-enhancing drug with an antioxidant drug in adults with schizophrenia.
Plain-language title generated from the registry record
Registry title: Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia
Key facts
- Where
- Taichung, TaiwanSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT04959201, who can take part
Where in Taiwan
- Department of Psychiatry, China Medical University HospitalTaichung, TaiwanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- China Medical University Hospital
- Trial code
- NCT04959201
- Record updated
- 23 October 2026
- Original description
Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with schizophrenia. In addition, several drugs with antioxidant properties have been tested in clinical trials for the treatment of schizophrenia too. Whether combined treatment of an NMDA-enhancing agent and a drug with antioxidant property can be better than an NMDA-enhancing agent alone deserves study.Read full original descriptionShow less
Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia
Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with schizophrenia. In addition, several drugs with antioxidant properties have been tested in clinical trials for the treatment of schizophrenia too. Whether combined treatment of an NMDA-enhancing agent and a drug with antioxidant property can be better than an NMDA-enhancing agent alone deserves study.
Inclusion: Have a DSM-5 (American Psychiatric Association) diagnosis of schizophrenia; Remain symptomatic but without clinically significant fluctuation, while their antipsychotic doses are unchanged for at least 3 months and will be maintained during the period of the 12-week trial; PANSS total score ≥ 60; Agree to participate in the study and provide informed consent.
Exclusion: DSM-5 diagnosis of intellectual disability or substance (including alcohol) use disorder; History of epilepsy, head trauma, stroke, or serious medical or central nervous system diseases (other than schizophrenia) which may interfere with the study; Clinically significant laboratory screening tests (including blood routine, biochemical tests); Pregnancy or lactation; Inability to follow protocol.